AAPL282.45-1.33 (-0.47%) ▼|ABBV255.01+1.66 (+0.66%) ▲|ABT94.36+0.24 (+0.25%) ▲|ACN126.51-2.47 (-1.92%) ▼|ADBE205.77+3.04 (+1.50%) ▲|AMAT696.79+69.95 (+11.16%) ▲|AMD523.43+1.85 (+0.35%) ▲|AMGN359.60+1.27 (+0.35%) ▲|AMT169.37-6.22 (-3.54%) ▼|AMZN241.47+8.78 (+3.77%) ▲|AVGO370.48+5.46 (+1.50%) ▲|AXP340.57+0.21 (+0.06%) ▲|BA214.78-2.48 (-1.14%) ▼|BAC58.14+0.26 (+0.44%) ▲|BKNG184.63+3.17 (+1.74%) ▲|BLK949.75-14.96 (-1.55%) ▼|BMY57.68+0.16 (+0.27%) ▲|BNY144.77+1.21 (+0.84%) ▲|BRK-B497.68-0.98 (-0.20%) ▼|C142.97+1.21 (+0.85%) ▲|CAT1,019.18+21.71 (+2.18%) ▲|CL91.52-0.55 (-0.60%) ▼|CMCSA24.78+1.61 (+6.93%) ▲|COF202.53-1.47 (-0.72%) ▼|COP104.59-1.37 (-1.29%) ▼|COST954.12+1.58 (+0.17%) ▲|CRM159.10+0.73 (+0.46%) ▲|CSCO117.49+3.72 (+3.27%) ▲|CVS104.22-0.12 (-0.12%) ▼|CVX168.87-2.19 (-1.28%) ▼|DE614.43+1.19 (+0.19%) ▲|DHR193.13-3.07 (-1.56%) ▼|DIS99.10+0.31 (+0.31%) ▲|DUK128.02-0.39 (-0.30%) ▼|EMR142.25-1.24 (-0.86%) ▼|FDX323.15+4.62 (+1.45%) ▲|GD350.29+3.58 (+1.03%) ▲|GE373.97+4.97 (+1.35%) ▲|GEV1,085.90+40.73 (+3.90%) ▲|GILD126.13-1.75 (-1.37%) ▼|GM77.57-0.53 (-0.68%) ▼|GOOG349.67+14.98 (+4.47%) ▲|GOOGL351.62+14.23 (+4.22%) ▲|GS1,022.97+3.36 (+0.33%) ▲|HD347.86-1.00 (-0.29%) ▼|HON237.93-5.49 (-2.25%) ▼|IBM274.26+2.63 (+0.97%) ▲|INTC125.84-2.48 (-1.93%) ▼|INTU268.35+0.63 (+0.23%) ▲|ISRG405.81+1.54 (+0.38%) ▲|JNJ255.38+0.72 (+0.28%) ▲|JPM331.47+2.42 (+0.74%) ▲|KO82.91+0.28 (+0.34%) ▲|LIN508.81-10.81 (-2.08%) ▼|LLY1,210.75+2.63 (+0.22%) ▲|LMT504.69-2.71 (-0.53%) ▼|LOW220.25-2.23 (-1.00%) ▼|LRCX409.96+30.87 (+8.14%) ▲|MA510.18+11.16 (+2.24%) ▲|MCD266.65-3.11 (-1.15%) ▼|MDLZ59.88-0.91 (-1.50%) ▼|MDT81.46+0.48 (+0.59%) ▲|META564.60+14.35 (+2.61%) ▲|MMM163.85-0.17 (-0.10%) ▼|MO73.38-0.41 (-0.56%) ▼|MRK128.99+0.33 (+0.25%) ▲|MS213.25+1.22 (+0.58%) ▲|MSFT371.38-1.59 (-0.43%) ▼|MU1,093.91-38.42 (-3.39%) ▼|NEE87.54-1.03 (-1.16%) ▼|NFLX75.19+1.38 (+1.87%) ▲|NKE41.23+0.48 (+1.17%) ▲|NOW100.79+2.45 (+2.49%) ▲|NVDA193.91+1.38 (+0.72%) ▲|ORCL149.04+0.51 (+0.34%) ▲|PEP139.07-2.32 (-1.64%) ▼|PFE24.17-0.12 (-0.49%) ▼|PG147.47-1.55 (-1.04%) ▼|PLTR115.77+2.84 (+2.51%) ▲|PM180.45-0.32 (-0.18%) ▼|QCOM191.79+2.40 (+1.27%) ▲|RTX188.03+0.04 (+0.02%) ▲|SBUX103.23-1.37 (-1.31%) ▼|SCHW90.99+0.32 (+0.35%) ▲|SO96.86-0.31 (-0.31%) ▼|SPG225.53-1.36 (-0.60%) ▼|T21.52-1.21 (-5.30%) ▼|TMO503.37-9.67 (-1.88%) ▼|TMUS174.00-8.68 (-4.75%) ▼|TSLA399.97+20.26 (+5.34%) ▲|TXN286.92+1.50 (+0.52%) ▲|UBER75.58-0.62 (-0.81%) ▼|UNH418.00-9.89 (-2.31%) ▼|UNP271.49+3.14 (+1.17%) ▲|UPS107.24-0.91 (-0.84%) ▼|USB61.48+0.57 (+0.93%) ▲|V341.64+5.41 (+1.61%) ▲|VZ43.30-3.25 (-6.97%) ▼|WFC84.27+0.41 (+0.49%) ▲|WMT114.68-1.01 (-0.87%) ▼|XOM135.76-0.78 (-0.57%) ▼|AAPL282.45-1.33 (-0.47%) ▼|ABBV255.01+1.66 (+0.66%) ▲|ABT94.36+0.24 (+0.25%) ▲|ACN126.51-2.47 (-1.92%) ▼|ADBE205.77+3.04 (+1.50%) ▲|AMAT696.79+69.95 (+11.16%) ▲|AMD523.43+1.85 (+0.35%) ▲|AMGN359.60+1.27 (+0.35%) ▲|AMT169.37-6.22 (-3.54%) ▼|AMZN241.47+8.78 (+3.77%) ▲|AVGO370.48+5.46 (+1.50%) ▲|AXP340.57+0.21 (+0.06%) ▲|BA214.78-2.48 (-1.14%) ▼|BAC58.14+0.26 (+0.44%) ▲|BKNG184.63+3.17 (+1.74%) ▲|BLK949.75-14.96 (-1.55%) ▼|BMY57.68+0.16 (+0.27%) ▲|BNY144.77+1.21 (+0.84%) ▲|BRK-B497.68-0.98 (-0.20%) ▼|C142.97+1.21 (+0.85%) ▲|CAT1,019.18+21.71 (+2.18%) ▲|CL91.52-0.55 (-0.60%) ▼|CMCSA24.78+1.61 (+6.93%) ▲|COF202.53-1.47 (-0.72%) ▼|COP104.59-1.37 (-1.29%) ▼|COST954.12+1.58 (+0.17%) ▲|CRM159.10+0.73 (+0.46%) ▲|CSCO117.49+3.72 (+3.27%) ▲|CVS104.22-0.12 (-0.12%) ▼|CVX168.87-2.19 (-1.28%) ▼|DE614.43+1.19 (+0.19%) ▲|DHR193.13-3.07 (-1.56%) ▼|DIS99.10+0.31 (+0.31%) ▲|DUK128.02-0.39 (-0.30%) ▼|EMR142.25-1.24 (-0.86%) ▼|FDX323.15+4.62 (+1.45%) ▲|GD350.29+3.58 (+1.03%) ▲|GE373.97+4.97 (+1.35%) ▲|GEV1,085.90+40.73 (+3.90%) ▲|GILD126.13-1.75 (-1.37%) ▼|GM77.57-0.53 (-0.68%) ▼|GOOG349.67+14.98 (+4.47%) ▲|GOOGL351.62+14.23 (+4.22%) ▲|GS1,022.97+3.36 (+0.33%) ▲|HD347.86-1.00 (-0.29%) ▼|HON237.93-5.49 (-2.25%) ▼|IBM274.26+2.63 (+0.97%) ▲|INTC125.84-2.48 (-1.93%) ▼|INTU268.35+0.63 (+0.23%) ▲|ISRG405.81+1.54 (+0.38%) ▲|JNJ255.38+0.72 (+0.28%) ▲|JPM331.47+2.42 (+0.74%) ▲|KO82.91+0.28 (+0.34%) ▲|LIN508.81-10.81 (-2.08%) ▼|LLY1,210.75+2.63 (+0.22%) ▲|LMT504.69-2.71 (-0.53%) ▼|LOW220.25-2.23 (-1.00%) ▼|LRCX409.96+30.87 (+8.14%) ▲|MA510.18+11.16 (+2.24%) ▲|MCD266.65-3.11 (-1.15%) ▼|MDLZ59.88-0.91 (-1.50%) ▼|MDT81.46+0.48 (+0.59%) ▲|META564.60+14.35 (+2.61%) ▲|MMM163.85-0.17 (-0.10%) ▼|MO73.38-0.41 (-0.56%) ▼|MRK128.99+0.33 (+0.25%) ▲|MS213.25+1.22 (+0.58%) ▲|MSFT371.38-1.59 (-0.43%) ▼|MU1,093.91-38.42 (-3.39%) ▼|NEE87.54-1.03 (-1.16%) ▼|NFLX75.19+1.38 (+1.87%) ▲|NKE41.23+0.48 (+1.17%) ▲|NOW100.79+2.45 (+2.49%) ▲|NVDA193.91+1.38 (+0.72%) ▲|ORCL149.04+0.51 (+0.34%) ▲|PEP139.07-2.32 (-1.64%) ▼|PFE24.17-0.12 (-0.49%) ▼|PG147.47-1.55 (-1.04%) ▼|PLTR115.77+2.84 (+2.51%) ▲|PM180.45-0.32 (-0.18%) ▼|QCOM191.79+2.40 (+1.27%) ▲|RTX188.03+0.04 (+0.02%) ▲|SBUX103.23-1.37 (-1.31%) ▼|SCHW90.99+0.32 (+0.35%) ▲|SO96.86-0.31 (-0.31%) ▼|SPG225.53-1.36 (-0.60%) ▼|T21.52-1.21 (-5.30%) ▼|TMO503.37-9.67 (-1.88%) ▼|TMUS174.00-8.68 (-4.75%) ▼|TSLA399.97+20.26 (+5.34%) ▲|TXN286.92+1.50 (+0.52%) ▲|UBER75.58-0.62 (-0.81%) ▼|UNH418.00-9.89 (-2.31%) ▼|UNP271.49+3.14 (+1.17%) ▲|UPS107.24-0.91 (-0.84%) ▼|USB61.48+0.57 (+0.93%) ▲|V341.64+5.41 (+1.61%) ▲|VZ43.30-3.25 (-6.97%) ▼|WFC84.27+0.41 (+0.49%) ▲|WMT114.68-1.01 (-0.87%) ▼|XOM135.76-0.78 (-0.57%) ▼|
27.6 C
New York
Monday, June 29, 2026

Tag: medical

newssourceFORcompanyinformationcontent1releasesmarket

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO

SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025.

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Algernon Announces Closing of the Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.

Exactech Reaches Consensual Agreement with Unsecured Creditors Committee, Completes Court Filing of Amended Plan

Plan Confirmation and Sale Approval Court Date Expected in Early September GAINESVILLE, Fla., July 24, 2025 /PRNewswire/ -- Exactech, a global medical technology leader, has filed...

Accesorios Reveals 150,000 Loyal Customers Built Through Six-Year Stealth Growth Strategy

Accesorios Ends Six-Year Stealth Operations, Reveals 150,000-Customer Base Built Through Word-of-Mouth

Dr. Joel Berley Launches 2026 Scholarship to Empower Aspiring Medical Leaders Nationwide

PLANTATION, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Dr. Joel Berley, a nationally respected oral surgeon and founder of Plantation Oral Surgery, is pleased to announce the official launch of the 2026 application cycle for the Dr. Joel Berley Scholarship for Future Doctors. This prestigious academic grant reflects Dr. Berley’s enduring mission to identify and uplift undergraduate students who are poised to become catalysts for progress in medicine.

Sugar Land Medical Weight Loss Expert, Dr. Adelola Ashaye, Launches Metabolic Wellness & Healthy Weight Program at InTouch Primary Care

Dr. Adelola Ashaye has launched Metabolic Wellness & Healthy Weight Program at InTouch Primary Care, offering a personalized, medically guided approach to sustainable weight loss...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Americase to Speak on Battery Regulations at 2025 OCP APAC Summit

Panel to explore regulatory challenges and alternatives to lithium-ion batteries in next-generation data centers WAXAHACHIE, Texas, July 24, 2025 /PRNewswire/ -- Americase, a leading manufacturer of...

The Frederick City Market Announces Relocation Starting August 3, 2025

FREDERICK, Md., July 24, 2025 /PRNewswire/ -- The Frederick City Market is relocating their weekly farmers and artisans market to 662 N. Market St,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers